Statement: Biden Administration Preparing for Potential FDA Approval of MDMA-Assisted Therapy for PTSD
July 27, 2022
Yesterday, a letter from the U.S. Department of Health and Human Services was made public describing the Food and Drug Administration’s “anticipated approval…within approximately 24 months” of …
MAPS Launches Psychedelic Fundamentals, an Online Education Curriculum From Leading Psychedelic Organization
July 14, 2022
Psychedelic Fundamentals is the initial offering in the new MAPS Digital Learning program introducing learners to the most important aspects of psychedelic history, research, uses, and harm reduction The …
MAPS Raises Nearly $1.6 Million in Christie’s NFT Auction
June 30, 2022
Historic Curated “Cartography of the Mind: A Curated NFT Sale” Auction is the First Time MAPS has Raised Money Using NFTs Beeple’s PILGRIMAGEPrice Realized: $252,000 Digital art, inspired by personal …
MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations
June 29, 2022
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System …
Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration
June 27, 2022
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated …
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
June 7, 2022
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board …
Christie’s Announces Cartography of the Mind: A Curated NFT Sale to Benefit MAPS
June 6, 2022
Christie’s is pleased to present Cartography of the Mind, a Curated NFT Sale to benefit the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with Ryan Zurrer, founder of …
Two Expanded Access Study Sites Now Open for Enrollment
May 11, 2022
Two new study sites are now enrolling for our MDMA-assisted therapy for PTSD Expanded Access program. The Pearl Institute in Waynesville, North Carolina, and Sage Integrative Health in Berkeley, California, …
MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
May 9, 2022
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
MAPS PLACES Fully Validated, Multi-Kilogram Synthesis MDMA in the PUblic Domain
April 5, 2022
MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices The availability of larger quantities …
Expanded Access Study Site in California Begins Screening
March 22, 2022
Our Expanded Access Program study site at Sage Integrative Health in Berkeley, California, began screening participants for MDMA-assisted therapy for PTSD in early March. Our multi-site expanded access …
Participant Experiences & “Cover Story”
March 1, 2022
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …